Healthcare Providers and Services
Company Overview of Seattle Children's Hospital
Seattle Children's Hospital operates as child health care and pediatric center in the United States. It offers adolescent gynecology, medicine, behavioral, and substance abuse programs; and ambulatory infusion, anesthesia, audiology, bioethics consultation, blood disorders, cancer, cardiac surgery, children with special needs, complex care, craniofacial center, critical care medicine, dental medicine, dialysis, eating disorders, endocrinology/diabetes, family advisory council, financial counseling, and gastroenterology services. The company also provides thoracic surgery, genetics, growth and feeding dynamics, gynecology, health information management, hematology, insurance and interpreter, ...
4800 Sand Point Way NE
Seattle, WA 98105
Founded in 1907
Key Executives for Seattle Children's Hospital
Chief Executive Officer and Trustee
Chief Financial Officer and Senior Vice President
President of Seattle Children's Hospital Research Institute
Compensation as of Fiscal Year 2014.
Seattle Children's Hospital Key Developments
Seattle Children's Hospital Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 11:30 AM
Jan 6 15
Seattle Children's Hospital Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Kelly Wallace, Chief Financial Officer and Senior Vice President.
Seattle Children's Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate in Children with Relapsed Leukemia
Dec 9 14
Seattle Children's announced that 11 of the 13 patients treated thus far in a clinical trial using genetically reprogrammed T cells to treat relapsed acute lymphoblastic leukemia have achieved complete remission, confirmed by highly sensitive tests designed to detect minute amounts of cancer cells. The trial includes patients with acute lymphoblastic leukemia who have relapsed after a bone marrow transplant and typically have only a 10% to 20% chance of survival with standard treatment. Using immunotherapy, which reprograms the body's T cells to hunt down and destroy cancer cells, researchers have seen an 85% complete remission rate. In the first phase of the trial, Gardner treated 13 patients with relapsed acute lymphoblastic leukemia using cancer immunotherapy. This phase was designed to demonstrate the safety and efficacy of cancer immunotherapy as a treatment for leukemia and to determine the optimal dose of engineered T cells to administer to patients. Of the 13 patients treated, 12 responded to the treatment and 11 achieved complete remission. One of these patients has since relapsed, the remaining ten are in ongoing remission. The second phase of the trial, which is expected to begin in 2015, will allow even more patients to be treated with what researchers determine is the optimal dose of reengineered T cells.
Seattle Children's Announces Retirement of Thomas N. Hansen as CEO in 2015
Jun 26 14
Seattle Children's announced that CEO Thomas N. Hansen, MD, will retire in 2015 as part of a long-planned transition of leadership. Hansen came to Seattle Children's as CEO in 2005. Prior to joining Seattle Children's, Hansen served as CEO of Columbus Children's Hospital and was Chair of the Department of Pediatrics at the School of Medicine of the Ohio State University.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|